Mixing Patient-Reported Outcome Modes During COVID-19 Date Published: May 05, 2020 Whitepaper Many clinical studies rely on site-based patient-reported outcome measures (PROMs), but the sudden requirement for social distancing and other restrictions because of the recent COVID-19 crisis necessitated adaptations to data collection strategies. Learn from eCOA and ePRO expert, Dr. Bill Byrom, how mixing modes of PRO data collection allows sponsors to continue conducting clinical trials during the pandemic. He also details why sponsors and sites need to consider the following: Existing equivalence data Identifying data captured by alternative methods Maintaining data integrity COVID-19 – Considerations for Mixing Modes of Patient-Reported Outcomes Data Collection Share: LinkedInTweet Recommended Resources 3 Themes and Takeaways From FDA’s Draft Guidance on DCTs Download Now Whitepaper Computerized Adaptive Tests Using PROMIS CAT Download Now Whitepaper The EMA Recommendation Paper on Decentralized Elements in Clinical Trials: An Overview Read Our White Paper Whitepaper